← Insider Monitor
NEKTAR THERAPEUTICS logo
NKTR

NEKTAR THERAPEUTICS

Nasdaq · Pharmaceutical Preparations

2
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Nektar Therapeutics is a biopharmaceutical company that develops drug candidates using its polymer chemistry-based platforms, focusing on immunology and inflammation treatments. It generates revenue both from its own pipeline and through licensing and collaboration agreements with other pharmaceutical companies.

Industry
Pharmaceutical Preparations
Headquarters
San Francisco, CA
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
ROBIN HOWARD WPresident & CEOSell$15KNov 17, 2026
Zalevsky JonathanChief R&D OfficerSell$7KNov 17, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for NKTR.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable NKTR activity by email

Free alerts for the insider and congressional trades worth watching.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.